{"id":20038,"date":"2025-11-01T23:20:45","date_gmt":"2025-11-01T17:50:45","guid":{"rendered":"http:\/\/43.205.138.160\/?post_type=article&#038;p=20038"},"modified":"2025-11-01T23:20:45","modified_gmt":"2025-11-01T17:50:45","slug":"%e0%a4%b5%e0%a4%bf%e0%a4%b6%e0%a5%8d%e0%a4%b5%e0%a4%be%e0%a4%b8-%e0%a4%b8%e0%a5%87-%e0%a4%ad%e0%a4%b5%e0%a4%bf%e0%a4%b7%e0%a5%8d%e0%a4%af-%e0%a4%95%e0%a5%80-%e0%a4%93%e0%a4%b0-gland-pharma","status":"publish","type":"article","link":"https:\/\/signalz.pro\/article\/%e0%a4%b5%e0%a4%bf%e0%a4%b6%e0%a5%8d%e0%a4%b5%e0%a4%be%e0%a4%b8-%e0%a4%b8%e0%a5%87-%e0%a4%ad%e0%a4%b5%e0%a4%bf%e0%a4%b7%e0%a5%8d%e0%a4%af-%e0%a4%95%e0%a5%80-%e0%a4%93%e0%a4%b0-gland-pharma\/","title":{"rendered":"&#8220;\u0935\u093f\u0936\u094d\u0935\u093e\u0938 \u0938\u0947 \u092d\u0935\u093f\u0937\u094d\u092f \u0915\u0940 \u0913\u0930\u2026 GLAND PHARMA \u0915\u0947 \u0938\u093e\u0925 Invest \u0915\u0930\u0947\u0902 \u0928\u093f\u0936\u094d\u091a\u093f\u0902\u0924 \u092e\u0928 \u0938\u0947 \u2013 \u0917\u0941\u0923\u0935\u0924\u094d\u0924\u093e, \u092a\u093e\u0930\u0926\u0930\u094d\u0936\u093f\u0924\u093e \u0914\u0930 \u0938\u094d\u0925\u093f\u0930\u0924\u093e \u0915\u093e \u092d\u0930\u094b\u0938\u093e \u0939\u0930 \u0915\u0926\u092e \u092a\u0930!&#8221;"},"content":{"rendered":"<p>Gland Pharma (NSE: GLAND) \u092b\u093f\u0932\u0939\u093e\u0932 \u0905\u092a\u0928\u0940 \u091a\u093e\u0932 \u092e\u0947\u0902 \u0907\u0902\u0921\u0947\u0915\u094d\u0938\u0947\u0938 \u0915\u0947 \u092e\u0941\u0915\u093e\u092c\u0932\u0947 \u0938\u0941\u0938\u094d\u0924 \u0939\u0948, \u091c\u092c\u0915\u093f NIFTY \u0914\u0930 BANK NIFTY \u092e\u0947\u0902 \u0924\u0947\u091c\u0940 \u0926\u093f\u0916 \u0930\u0939\u0940 \u0939\u0948\u0964 \u0907\u0938\u0915\u0947 03 \u0928\u0935\u0902\u092c\u0930 \u0915\u094b Q2 \u0930\u093f\u091c\u0932\u094d\u091f\u094d\u0938 \u0930\u093f\u0932\u0940\u091c\u093c \u0939\u094b\u0928\u0947 \u0935\u093e\u0932\u0947 \u0939\u0948\u0902, \u091c\u093f\u0938\u0938\u0947 \u0935\u0949\u0932\u094d\u092f\u0942\u092e \u0914\u0930 \u0935\u094b\u0932\u0948\u091f\u093f\u0932\u093f\u091f\u0940 \u092c\u0922\u093c \u0938\u0915\u0924\u0940 \u0939\u0948\u0964 \u0906\u0917\u0947 \u0926\u0947\u0916\u0947\u0902 \u092a\u0942\u0930\u093e \u0935\u093f\u0936\u094d\u0932\u0947\u0937\u0923 \u0914\u0930 \u0935\u094d\u092f\u093e\u0935\u0938\u093e\u092f\u093f\u0915 \u0938\u0932\u093e\u0939:<\/p>\n<p><strong>Technical Analysis<br \/>\n<\/strong>\u0938\u094d\u091f\u0949\u0915 \u0915\u0948\u0902\u0921\u0932 \u092a\u0948\u091f\u0930\u094d\u0928 \u092e\u0947\u0902 \u092a\u093f\u091b\u0932\u0947 \u0915\u0941\u091b \u0939\u092b\u094d\u0924\u094b\u0902 \u0938\u0947 \u0938\u093e\u0907\u0921\u0935\u0947\u091c\u093c \u092e\u0942\u0935\u092e\u0947\u0902\u091f \u0914\u0930 \u0935\u0949\u0932\u094d\u092f\u0942\u092e \u092e\u0947\u0902 \u0917\u093f\u0930\u093e\u0935\u091f \u0926\u093f\u0916\u0940 \u0939\u0948, \u091c\u092c\u0915\u093f \u0936\u0949\u0930\u094d\u091f-\u091f\u0930\u094d\u092e \u092e\u0947\u0902 1920\u20131950 \u0915\u0947 \u0906\u0938\u092a\u093e\u0938 \u0930\u0947\u091c\u093f\u0938\u094d\u091f\u0947\u0902\u0938 \u0939\u0948\u0964\u200b<\/p>\n<ul>\n<li>\u0938\u092d\u0940 \u092a\u094d\u0930\u092e\u0941\u0916 SMAs\/EMAs (5, 10, 20, 50, 100, 200) \u0905\u092d\u0940 \u092d\u0940 \u0938\u0915\u093e\u0930\u093e\u0924\u094d\u092e\u0915 \u091f\u094d\u0930\u0947\u0902\u0921 \u0915\u093e \u0938\u0902\u0915\u0947\u0924 \u0926\u0947 \u0930\u0939\u0947 \u0939\u0948\u0902\u0964\u200b<\/li>\n<li>RSI, MACD \u0914\u0930 \u0905\u0928\u094d\u092f \u092c\u0941\u0932\u093f\u0936 \u0938\u0902\u0915\u0947\u0924\u094b\u0902 \u0915\u0947 \u092c\u093e\u0935\u091c\u0942\u0926, \u0938\u094d\u091f\u0949\u0915 -0.83% \u0915\u0947 \u0938\u093e\u0932\u093e\u0928\u093e \u0930\u093f\u091f\u0930\u094d\u0928 \u0915\u0947 \u0938\u093e\u0925 \u0907\u0902\u0921\u0947\u0915\u094d\u0938 \u0915\u0947 \u092e\u0941\u0915\u093e\u092c\u0932\u0947 \u0915\u092e\u091c\u094b\u0930 \u0939\u0948\u0964\u200b\u200b<\/li>\n<li>\u0915\u094d\u0935\u093f\u0915 \u0938\u092a\u094b\u0930\u094d\u091f \u0932\u0947\u0935\u0932\u094d\u0938 1900\u20131875 \u0914\u0930 \u0930\u0947\u091c\u093f\u0938\u094d\u091f\u0947\u0902\u0938 1950\/1985 \u092a\u0930 \u0939\u0948\u0902\u0964<\/li>\n<\/ul>\n<p><strong>Fundamental Analysis <\/strong><\/p>\n<ul>\n<li>\u092e\u093e\u0930\u094d\u0915\u0947\u091f \u0915\u0948\u092a \u0932\u0917\u092d\u0917 \u20b931,674 \u0915\u0930\u094b\u0921\u093c, PE Ratio 41.2 \u0914\u0930 ROCE 11.44% \u0939\u0948, \u091c\u094b \u0935\u0948\u0932\u094d\u092f\u0941\u090f\u0936\u0928 \u0915\u0947 \u0939\u093f\u0938\u093e\u092c \u0938\u0947 \u0925\u094b\u0921\u093c\u093e \u092a\u094d\u0930\u0940\u092e\u093f\u092f\u092e \u0939\u0948\u0964\u200b<\/li>\n<li>\u0915\u0902\u092a\u0928\u0940 \u0915\u093e \u0938\u093e\u0932\u093e\u0928\u093e \u0930\u0947\u0935\u0947\u0928\u094d\u092f\u0942 5720 \u0915\u0930\u094b\u0921\u093c \u0915\u0947 \u0906\u0938-\u092a\u093e\u0938 \u0939\u0948, \u0914\u0930 EBITDA \u092e\u093e\u0930\u094d\u091c\u093f\u0928 ~21-34% \u0930\u0939\u093e \u0939\u0948\u0964 \u092a\u093f\u091b\u0932\u0940 \u0924\u093f\u092e\u093e\u0939\u0940 \u092e\u0947\u0902 \u0928\u0947\u091f \u092a\u094d\u0930\u0949\u092b\u093f\u091f \u092e\u0947\u0902 \u0915\u0930\u0940\u092c 16% \u0915\u0940 \u0917\u093f\u0930\u093e\u0935\u091f \u0906\u0908 \u0925\u0940, \u0932\u0947\u0915\u093f\u0928 \u092c\u0947\u0938 \u092c\u093f\u091c\u0928\u0947\u0938 \u0938\u094d\u091f\u094d\u0930\u0949\u0928\u094d\u0917 \u092c\u0928\u093e \u0939\u0941\u0906 \u0939\u0948\u0964\u200b<\/li>\n<li>\u0917\u094d\u0930\u094b\u0925 \u0906\u0909\u091f\u0932\u0941\u0915: \u0905\u0917\u0932\u0947 \u0924\u0940\u0928 \u0938\u093e\u0932\u094b\u0902 \u092e\u0947\u0902 25% \u0915\u0947 \u0906\u0938\u092a\u093e\u0938 EPS \u0917\u094d\u0930\u094b\u0925 \u0914\u0930 13% \u0915\u0947 \u0906\u0938\u092a\u093e\u0938 \u0930\u0947\u0935\u0947\u0928\u094d\u092f\u0942 \u0917\u094d\u0930\u094b\u0925 \u0915\u093e \u0905\u0928\u0941\u092e\u093e\u0928 \u0939\u0948, \u091c\u092c\u0915\u093f ROE 11.6% \u0930\u0939 \u0938\u0915\u0924\u093e \u0939\u0948\u0964\u200b<\/li>\n<\/ul>\n<p><strong>Q2 Result Expectation <\/strong><\/p>\n<ul>\n<li>Q2 \u0930\u093f\u091c\u0932\u094d\u091f\u094d\u0938 03 \u0928\u0935\u0902\u092c\u0930 \u0915\u094b \u091c\u093e\u0930\u0940 \u0939\u094b\u0902\u0917\u0947, \u092a\u093f\u091b\u0932\u0947 \u0915\u094d\u0935\u0949\u0930\u094d\u091f\u0930 \u0915\u0940 \u0924\u0941\u0932\u0928\u093e \u092e\u0947\u0902 \u0915\u0902\u092a\u0928\u0940 US \u092e\u093e\u0930\u094d\u0915\u0947\u091f \u092e\u0947\u0902 \u0917\u094d\u0930\u094b\u0925 \u0926\u093f\u0916\u093e \u0938\u0915\u0924\u0940 \u0939\u0948, \u092a\u0930 Cenexi (\u092b\u094d\u0930\u0947\u0902\u091a \u092f\u0942\u0928\u093f\u091f) \u092e\u0947\u0902 \u0936\u091f\u0921\u093e\u0909\u0928 \u0915\u0947 \u0915\u093e\u0930\u0923 \u0915\u0902\u0938\u094b\u0932\u093f\u0921\u0947\u091f\u0947\u0921 \u092e\u093e\u0930\u094d\u091c\u093f\u0928 \u0926\u092c\u093e\u0935 \u092e\u0947\u0902 \u0930\u0939 \u0938\u0915\u0924\u0947 \u0939\u0948\u0902\u0964\u200b<\/li>\n<li>EBITDA \u0914\u0930 \u0930\u0947\u0935\u0947\u0928\u094d\u092f\u0942 \u092e\u0947\u0902 \u0939\u0932\u094d\u0915\u0940 \u092a\u0949\u091c\u093f\u091f\u093f\u0935 \u0917\u094d\u0930\u094b\u0925, \u0932\u0947\u0915\u093f\u0928 \u092a\u094d\u0930\u0949\u092b\u093f\u091f \u092e\u0947\u0902 \u092b\u094d\u0932\u0948\u091f \u092f\u093e \u092e\u093e\u092e\u0942\u0932\u0940 \u0917\u093f\u0930\u093e\u0935\u091f \u0938\u0902\u092d\u0935\u0964\u200b<\/li>\n<\/ul>\n<p><strong>Entry Levels &amp; Strategy <\/strong><\/p>\n<ul>\n<li>\u0917\u093f\u0930\u093e\u0935\u091f \u092a\u0930 1900\u20131880 \u0915\u0947 \u0932\u0947\u0935\u0932 \u092a\u0930 \u092b\u0930\u094d\u0938\u094d\u091f \u091f\u094d\u0930\u0947\u0902\u091a \u092e\u0947\u0902 \u090f\u0902\u091f\u094d\u0930\u0940 \u0915\u0930\u0947\u0902\u0964 \u0924\u0947\u091c\u093c\u0940 \u0906\u0928\u0947 \u092a\u0930 1950\/1985 \u0915\u0947 \u0930\u0947\u091c\u093f\u0938\u094d\u091f\u0947\u0902\u0938 \u092a\u0930 \u092c\u0941\u0915\u093f\u0902\u0917 \u0914\u0930 \u092c\u094d\u0930\u0947\u0915\u0906\u0909\u091f \u0915\u0940 \u0915\u0902\u0921\u0940\u0936\u0928 \u0926\u0947\u0916\u0947\u0902\u0964\u200b<\/li>\n<li>\u0930\u093f\u091c\u0932\u094d\u091f \u0915\u0947 \u092c\u093e\u0926 \u0935\u094b\u0932\u0948\u091f\u093f\u0932\u093f\u091f\u0940 \u092c\u0922\u093c \u0938\u0915\u0924\u0940 \u0939\u0948, \u0907\u0938\u0932\u093f\u090f \u0938\u094d\u0932\u093f\u092a\u0947\u091c\u093c \u0915\u0947 \u091c\u094b\u0916\u093f\u092e \u0915\u0947 \u0938\u093e\u0925 \u0938\u094d\u091f\u0949\u092a\u0932\u0949\u0938 1850 \u0915\u0947 \u0928\u0940\u091a\u0947 \u0930\u0916\u0947\u0902\u0964<\/li>\n<\/ul>\n<p><strong>News Events &amp; Triggers <\/strong><\/p>\n<ul>\n<li>03 \u0928\u0935\u0902\u092c\u0930 \u0915\u094b \u0915\u0902\u092a\u0928\u0940 \u0915\u0947 \u0915\u094d\u0935\u093e\u0930\u094d\u091f\u0930\u0932\u0940 \u0930\u093f\u091c\u0932\u094d\u091f\u094d\u0938 \u0939\u0948\u0902 \u0914\u0930 \u0907\u0938\u0940 \u0926\u093f\u0928 \u0907\u0928\u094d\u0935\u0947\u0938\u094d\u091f\u0930\/\u090f\u0928\u093e\u0932\u093f\u0938\u094d\u091f \u0915\u0949\u0932 \u092d\u0940 \u0939\u0948\u0964\u200b<\/li>\n<li>Cenexi \u0915\u0947 \u0911\u092a\u0930\u0947\u0936\u0928\u094d\u0938, US FDA \u0905\u092a\u0921\u0947\u091f\u094d\u0938, \u0914\u0930 \u0928\u0908 \u092a\u094d\u0930\u0949\u0921\u0915\u094d\u091f \u092a\u093e\u0907\u092a\u0932\u093e\u0907\u0928 \u092f\u093e R&amp;D \u0907\u0928\u094d\u0935\u0947\u0938\u094d\u091f\u092e\u0947\u0902\u091f\u094d\u0938 \u092d\u0940 \u0905\u0917\u0932\u0947 \u0915\u0941\u091b \u092e\u0939\u0940\u0928\u094b\u0902 \u092e\u0947\u0902 \u092e\u0942\u0932\u094d\u092f \u0915\u094b \u092a\u094d\u0930\u092d\u093e\u0935\u093f\u0924 \u0915\u0930 \u0938\u0915\u0924\u0947 \u0939\u0948\u0902\u0964\u200b<\/li>\n<\/ul>\n<p><strong>Disclaimer &amp; Disclosure<br \/>\n<\/strong>&#8220;\u092f\u0939 \u0915\u0947\u0935\u0932 \u091c\u093e\u0928\u0915\u093e\u0930\u0940 \u0914\u0930 \u0936\u0948\u0915\u094d\u0937\u0923\u093f\u0915 \u0909\u0926\u094d\u0926\u0947\u0936\u094d\u092f\u094b\u0902 \u0915\u0947 \u0932\u093f\u090f \u0939\u0948\u0964 \u0907\u0938\u092e\u0947\u0902 \u0926\u0940 \u0917\u0908 \u0930\u093e\u092f \u092e\u0947\u0930\u0940 \u0935\u094d\u092f\u0915\u094d\u0924\u093f\u0917\u0924 \u0930\u093f\u0938\u0930\u094d\u091a \u092a\u0930 \u0906\u0927\u093e\u0930\u093f\u0924 \u0939\u0948\u0964 \u0928\u093f\u0935\u0947\u0936 \u091c\u094b\u0916\u093f\u092e \u0915\u0947 \u0905\u0927\u0940\u0928 \u0939\u0948\u0964 \u0915\u0943\u092a\u092f\u093e SEBI \u0930\u091c\u093f\u0938\u094d\u091f\u0930\u094d\u0921 \u0938\u0932\u093e\u0939\u0915\u093e\u0930 \u0938\u0947 \u0938\u0932\u093e\u0939 \u0932\u0947\u0915\u0930 \u0939\u0940 \u0928\u093f\u0930\u094d\u0923\u092f \u0932\u0947\u0902\u0964 \u0932\u0947\u0916\u0915 \u0915\u093e \u0928 \u0924\u094b \u0907\u0938 \u0938\u094d\u091f\u0949\u0915 \u092e\u0947\u0902 \u0915\u094b\u0908 \u092a\u094b\u091c\u0940\u0936\u0928 \u0939\u0948 \u0914\u0930 \u0928 \u0939\u0940 \u0915\u0902\u092a\u0928\u0940 \u0938\u0947 \u0915\u094b\u0908 \u0932\u093e\u092d \u0938\u0902\u092c\u0902\u0927 \u0939\u0948\u0964&#8221;<\/p>\n<p><strong>Summary<\/strong>:<br \/>\nGland Pharma \u0915\u0947 Q2 \u092a\u0930\u093f\u0923\u093e\u092e\u094b\u0902 \u092e\u0947\u0902 \u0932\u093f\u092e\u093f\u091f\u0947\u0921 \u0917\u094d\u0930\u094b\u0925 \u0915\u0940 \u0909\u092e\u094d\u092e\u0940\u0926, \u0932\u0947\u0915\u093f\u0928 \u092e\u094c\u091c\u0942\u0926\u093e \u0935\u0948\u0932\u094d\u092f\u0941\u090f\u0936\u0928 \u0914\u0930 \u0935\u0949\u0932\u094d\u092f\u0942\u092e \u0935\u0940\u0915\u0928\u0947\u0938 \u0915\u0947 \u0915\u093e\u0930\u0923 1880\u20131900 \u091c\u094b\u0928 \u0915\u093e \u0935\u0947\u091f \u0915\u0930\u0947\u0902\u0964 \u0928\u094d\u092f\u0942\u091c\u093c\/\u0907\u0935\u0947\u0902\u091f\u094d\u0938 \u0914\u0930 \u0917\u094d\u0932\u094b\u092c\u0932 \u092b\u093e\u0930\u094d\u092e\u093e \u0905\u092a\u0921\u0947\u091f\u094d\u0938 \u0915\u094b \u092d\u0940 \u0927\u094d\u092f\u093e\u0928 \u092e\u0947\u0902 \u0930\u0916\u0947\u0902.\u200b\u200b<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"template":"","article-category":[35],"article-tags":[787,761,385,386,400,130,163,133,169,162,168,127,155],"class_list":["post-20038","article","type-article","status-publish","hentry","article-category-learn","article-tags-nifty-banknifty","article-tags-nifty-banknifty-optiondata","article-tags-optionbuying","article-tags-optionstrading","article-tags-technicalanalysis","article-tags-expert-analysis","article-tags-financialeducation","article-tags-investment-strategies","article-tags-investmentstrategy","article-tags-stockmarket","article-tags-stockmarkettips","article-tags-successful-investing","article-tags-wealthbuilding"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/20038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=20038"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=20038"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=20038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}